No sooner had cytokine therapies been labelled an area to watch in 2018 than Bristol-Myers Squibb paid a massive $1.85bn for rights to Nektar’s NKTR-214, and interest in IL-2 is not about to abate. Read More

Discover the wealth of resources MassBio offers its members including a crowdsourced Knowledge Base, resources for entrepreneurs, funding opportunities and MassBio’s policy work.
Read the latest white papers, case studies and other resources shared by MassBio members.
Read & contributeHear from the budding life sciences entrepreneurs with brilliant ideas and seasoned mentors advising them through MassCONNECT.
TestimonialsEmployees of MassBio® member companies are granted exclusive access to the Knowledge Base to benefit from the rich content it houses. Share your latest white papers, case studies and more in the MassBio Knowledge Base.
Entrepreneurs can discover valuable resources through the Knowledge Base and can apply to participate in MassCONNECT, a mentorship program that helps budding entrepreneurs develop a business plan, perfect his or her pitch and connect with possible funding opportunities.
MassBio not only strives to strengthen the life sciences entrepreneurial community, but the entire life sciences ecosystem. We regularly share funding opportunities spanning across therapeutic areas.
At MassBio, we work diligently to educate on and advocate for an industry that is vital to the Massachusetts economy and that is improving the lives of patients around the world. Stay current on all the latest issues facing the industry and learn how MassBio advocates for you!
No sooner had cytokine therapies been labelled an area to watch in 2018 than Bristol-Myers Squibb paid a massive $1.85bn for rights to Nektar’s NKTR-214, and interest in IL-2 is not about to abate. Read More
Learn about grants and other funding opportunities that are currently available.
Meet the people at the heart of what life sciences companies do: the patients.
Read the latest life sciences policy updates from Washington, D.C.